Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Irinotecan and Temozolomide in Participants With Relapsed or Refractory Ewing’s Sarcoma
Protocol ID
CAMPFIRE- J1S-MC-JP04
Disease (Sub Disease)
Ewing Sarcoma
Diagnosis Stage
Relapsed/refractory
Location
NSW, VIC
Sponsor
Eli Lilly and Company
Links
Trial Status
Open
Sites
Royal Children's Hospital
The Children's Hospital at Westmead
The Children's Hospital at Westmead
Study Type
Treatment
Phase
Phase 2
Age Eligibility
1 Year to 39 Years
International registry ID's
NCT05440786
| Study Title | A Randomized Open-Label Phase 2 Study Evaluating Abemaciclib in Combination With Irinotecan and Temozolomide in Participants With Relapsed or Refractory Ewing’s Sarcoma |
|---|---|
| Protocol ID | CAMPFIRE- J1S-MC-JP04 |
| Disease (Sub Disease) | Ewing Sarcoma |
| Diagnosis Stage | Relapsed/refractory |
| Location | NSW / VIC |
| Sponsor | Eli Lilly and Company |
| Links | https://clinicaltrials.gov/ct2/show/NCT05440786 |
| Trial Status | Open |
| Trial Open Date | 10/09/2022 |
| Sites | Royal Children's Hospital / The Children's Hospital at Westmead |
| Study Type | Treatment |
| Phase | Phase 2 |
| Age Eligibility | 1 Year to 39 Years |
| International registry ID's | NCT05440786 |